Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

25. Oktober 2025 11:01 ET | Quelle: Sobi, Inc.

Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions

NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS...
07. November 2024 06:59 ET | Quelle: Sobi, Inc.

Sobi to present new data across its immunology portfolio at the ACR Convergence 2024

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced the presentation of four abstracts that...
24. Mai 2024 15:16 ET | Quelle: Sobi, Inc.

Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome

FDA has granted Fast Track designation to emapalumab-lzsg for the potential first therapeutic option in patients with MAS
04. April 2023 07:00 ET | Quelle: Sobi, Inc.

Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome

WALTHAM, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), today announced that the Annals of Rheumatic...